Sector Focus


Caliber has successfully planned with both venture backed private development stage companies and publicly traded biopharmaceutical companies. We understand the unique challenges of emerging companies as well as global biotech organizations and we have developed a keen sense of what it takes to discover and develop biologically derived treatments to enhance the quality of care in markets with substantially under met medical needs.


Ambit Biosciences Corporation

Ambit Biosciences Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Their pipeline currently includes three programs, each discovered internally and each aimed at the inhibition of validated kinase targets. Their lead drug candidate, quizartinib, is a once-daily, orally administered FMS-like tyrosine kinase 3, or FLT3, kinase inhibitor.

Search Projects

  • Board of Directors
  • Vice President Regulatory Affairs and Quality Assurance